Translational Neurodegeneration

Scope & Guideline

Bridging Discovery and Clinical Insight in Neuroscience

Introduction

Welcome to the Translational Neurodegeneration information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Translational Neurodegeneration, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2047-9158
PublisherBMC
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Convergefrom 2012 to 2024
AbbreviationTRANSL NEURODEGENER / Transl. Neurodegener.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

Translational Neurodegeneration focuses on advancing our understanding of neurodegenerative diseases through innovative research, bridging basic science with clinical applications. The journal aims to publish high-quality studies that contribute to the diagnosis, treatment, and understanding of the mechanisms underlying various neurodegenerative disorders.
  1. Mechanistic Insights into Neurodegeneration:
    The journal emphasizes research that elucidates the biological and molecular mechanisms involved in neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS). This includes studies on protein misfolding, neuroinflammation, and cellular pathways.
  2. Biomarker Development and Validation:
    A core area of focus is the identification and validation of biomarkers for early diagnosis and monitoring of neurodegenerative diseases. This includes both central nervous system (CNS) markers and peripheral biomarkers.
  3. Therapeutic Innovations:
    The journal highlights novel therapeutic strategies, including pharmacological interventions, gene therapy, and lifestyle modifications aimed at mitigating the progression of neurodegenerative diseases.
  4. Translational Research:
    Translational Neurodegeneration prioritizes studies that bridge the gap between laboratory findings and clinical applications, ensuring that basic research informs clinical practices and vice versa.
  5. Impact of Environmental and Lifestyle Factors:
    Research exploring how environmental influences, such as diet, exercise, and microbial factors, contribute to neurodegenerative disease pathogenesis is a significant aspect of the journal's aims.
Translational Neurodegeneration is increasingly reflecting the evolving landscape of neurodegenerative research. The following themes have gained traction, indicating where future research efforts and funding may be directed.
  1. Microbiome and Neurodegeneration:
    Recent publications have shown a significant increase in research examining the relationship between gut microbiota and neurodegenerative diseases, highlighting the potential for gut-brain axis interventions.
  2. Extracellular Vesicles and Biomarkers:
    There is a growing interest in utilizing extracellular vesicles as non-invasive biomarkers for diagnosing and monitoring neurodegenerative diseases, reflecting a trend towards more accessible diagnostic tools.
  3. Targeting Neuroinflammation:
    Research focusing on neuroinflammation and its role in neurodegeneration is on the rise, with studies investigating various therapeutic targets within inflammatory pathways.
  4. Personalized Medicine Approaches:
    Emerging themes include the development of personalized medicine strategies, utilizing genetic and molecular profiling to tailor therapies for individual patients, particularly in diseases like ALS and Alzheimer's.
  5. Innovative Delivery Mechanisms:
    There is an increasing focus on novel delivery systems for therapeutics, such as nanotechnology and gene therapy, aimed at enhancing treatment efficacy and targeting specific neurodegenerative processes.

Declining or Waning

While certain themes remain robust within the journal, others appear to be declining in prominence over recent publications. This section identifies areas that are seeing reduced focus or are less frequently addressed in new research.
  1. Traditional Pharmacological Approaches:
    There has been a noticeable decrease in studies focusing solely on traditional pharmacological treatments for neurodegenerative diseases without integrating novel therapeutic approaches or innovative delivery systems.
  2. Basic Animal Models:
    Research utilizing basic animal models without advanced genetic manipulations or disease modeling techniques appears to be waning. The trend is shifting towards more sophisticated models that closely mimic human disease pathology.
  3. Single Disease Focus:
    The journal is moving away from studies that exclusively focus on a single neurodegenerative disease. There is a growing trend toward research that explores overlaps and interactions among various neurodegenerative conditions.

Similar Journals

AIMS Neuroscience

Empowering minds with cutting-edge neuroscience insights.
Publisher: AMER INST MATHEMATICAL SCIENCES-AIMSISSN: 2373-8006Frequency: 4 issues/year

AIMS Neuroscience is an esteemed open-access journal published by the American Institute of Mathematical Sciences (AIMS), dedicated to advancing the field of neuroscience since its inception in 2014. With a robust ISSN of 2373-8006 and an E-ISSN of 2373-7972, this journal aims to provide a platform for innovative research and scholarly discourse that spans the diverse and dynamic landscape of the neuroscience discipline. As of 2023, it holds a respectable Q3 category ranking in the miscellaneous neuroscience field and ranks #65 out of 113 in general neuroscience according to Scopus, positioning it in the 42nd percentile for impact. AIMS Neuroscience encompasses a broad scope of topics, from neurobiology and cognitive neuroscience to computational models and neuroengineering, making it a vital resource for researchers, professionals, and students alike. The journal's commitment to open access ensures that cutting-edge research is freely available, fostering collaboration and knowledge sharing within the global neuroscience community.

FASEB JOURNAL

Innovating Knowledge in Life Sciences and Beyond
Publisher: WILEYISSN: 0892-6638Frequency: 12 issues/year

FASEB JOURNAL, published by Wiley, stands as a leading interdisciplinary platform in the realm of biological sciences, prominently featured in the United States. With an impressive 2023 impact factor placing it in the Q1 category across various fields including Biochemistry, Biotechnology, Genetics, Molecular Biology, and Medicine (miscellaneous), the journal is recognized for its substantial contribution to advancing knowledge and innovation. It serves as a vital resource for researchers, professionals, and students alike, providing high-quality, peer-reviewed articles that explore the molecular and cellular mechanisms underlying health and disease. The FASEB JOURNAL not only emphasizes accessible scientific communication but also fosters collaboration within these dynamic fields, making it an essential publication for anyone engaged in cutting-edge life sciences research. To explore more about the journal's offerings and access its vast repository of scholarly articles, visit their official page.

Molecular Brain

Exploring the Intricacies of Cellular and Molecular Neuroscience
Publisher: BMCISSN: Frequency: 1 issue/year

Molecular Brain is a prestigious open-access journal published by BMC, dedicated to advancing the field of neuroscience with a particular focus on cellular and molecular mechanisms. Since its inception in 2008, the journal has been committed to disseminating high-quality research that explores the intricate workings of the brain, particularly in areas related to cellular and molecular neuroscience. Located in the heart of London, England, Molecular Brain has garnered significant recognition in the academic community, boasting a 2023 categorization in the Q2 quartile for both Cellular and Molecular Neuroscience and Molecular Biology, reflecting its growing influence and relevance in these fields. With its Scopus ranks placing it in the top 32% and 38% of its respective categories, the journal serves as an essential platform for researchers, professionals, and students alike, encouraging collaboration and knowledge-sharing through its accessible online format.

npj Aging and Mechanisms of Disease

Empowering Research for a Healthier Future
Publisher: NATURE PORTFOLIOISSN: Frequency: 1 issue/year

npj Aging and Mechanisms of Disease is a leading open-access journal dedicated to advancing the understanding of the biological mechanisms underlying aging and age-related diseases. Published by NATURE PORTFOLIO in the United Kingdom, this journal has established itself as a vital resource within the fields of Aging and Geriatrics and Gerontology, proudly holding a prestigious Q1 ranking in both categories as of 2023. With an impressive Scopus ranking, placing it in the top 10 for Geriatrics and Gerontology, and the top 9 for Aging, the journal is committed to disseminating high-quality, peer-reviewed research that offers innovative insights and fosters collaboration among researchers and practitioners. Since its inception in 2015, npj Aging and Mechanisms of Disease has embraced the open-access model, ensuring that groundbreaking findings are freely available to all, thereby promoting widespread knowledge-sharing within the scientific community. This journal serves as an essential platform for those seeking to explore the complex interplay of genetic, molecular, and environmental factors that influence aging and its associated challenges.

Molecular Neurodegeneration

Unlocking the mysteries of neurodegeneration.
Publisher: BMCISSN: Frequency: 1 issue/year

Molecular Neurodegeneration is a leading journal published by BMC, dedicated to advancing the field of neurodegeneration through high-quality, open-access research. Since its inception in 2006, this peer-reviewed journal has provided a pivotal platform for the dissemination of innovative findings in the realms of Cellular and Molecular Neuroscience, Molecular Biology, and Clinical Neurology. With a stellar impact factor and listed in the prestigious Q1 category in multiple relevant categories, it ranks among the top publications in the field—specifically, it holds the #3 position in Neuroscience and #6 position in Clinical Neurology based on Scopus metrics. Researchers, professionals, and students alike will find significant value in the open access format, which fosters unrestricted sharing of knowledge, ensuring that emerging ideas in neurodegeneration reach a global audience. Based in London, United Kingdom, the journal promises a comprehensive scope that addresses critical questions in neurobiology, making it an essential resource for anyone interested in the molecular mechanisms underlying neurodegenerative diseases.

NEUROMOLECULAR MEDICINE

Driving Discovery in Neuromolecular Research
Publisher: HUMANA PRESS INCISSN: 1535-1084Frequency: 4 issues/year

NEUROMOLECULAR MEDICINE, published by HUMANA PRESS INC, is a prestigious peer-reviewed journal dedicated to advancing the fields of cellular and molecular neuroscience, molecular medicine, and neurology. With an ISSN of 1535-1084 and an E-ISSN of 1559-1174, the journal boasts a significant presence in academic research since its inception in 2002 and continues to publish cutting-edge studies through 2024. Ranked in the Q2 category for 2023 in various disciplines, including Neuroscience and Molecular Medicine, it holds impressive positions in Scopus rankings, including 41st out of 192 in Neuroscience and Neurology. Although not an open access journal, NEUROMOLECULAR MEDICINE remains invaluable for researchers, professionals, and students seeking to explore the intricate relationships between molecular mechanisms and neurological functions, thereby contributing to the scientific understanding of nervous system diseases and therapeutic innovations.

Acta Neuropathologica Communications

Connecting Discoveries in Neurology and Pathology.
Publisher: BMCISSN: 2051-5960Frequency: 1 issue/year

Acta Neuropathologica Communications is a distinguished open-access journal published by BMC since 2013, focusing on the rapidly advancing fields of neurology, cellular and molecular neuroscience, and pathology. Located in the United Kingdom, this journal serves as a vital platform for researchers to disseminate significant findings that enhance our understanding of neurological disorders and their underlying mechanisms. With an impressive impact factor reflected in its Q1 ranking across multiple relevant categories, including Cellular and Molecular Neuroscience, Neurology (Clinical), and Pathology and Forensic Medicine, Acta Neuropathologica Communications stands out in the academic community for its rigorous peer-review process and commitment to high-quality research. The journal’s Scopus rankings highlight its global relevance, placing it in the top percentiles among leading research publications. Researchers, professionals, and students alike are encouraged to access and contribute to this essential resource, fostering a collaborative and informed approach to tackling the complexities of neuropathology and neuroscience.

Journal of Central Nervous System Disease

Exploring the frontiers of neuroscience.
Publisher: SAGE PUBLICATIONS LTDISSN: 1179-5735Frequency: 1 issue/year

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

FASEB BioAdvances

Connecting Researchers Through Open Access Science
Publisher: WILEYISSN: Frequency: 12 issues/year

FASEB BioAdvances, published by WILEY, is an esteemed open-access journal dedicated to advancing the fields of biochemistry, molecular biology, and physiology. Since its inception in 2019, the journal has rapidly established a significant presence within the academic community, boasting an impressive impact factor reflective of its Q2 and Q3 standings across various categories, including Biochemistry, Genetics and Molecular Biology, Cancer Research, Molecular Medicine, and Physiology. The journal aims to disseminate high-quality research and innovative findings to enhance the understanding of biological processes, making it a vital resource for researchers, professionals, and students alike. With its commitment to open access, FASEB BioAdvances ensures that groundbreaking research is available to a global audience, facilitating collaboration and exploration in these rapidly evolving scientific domains.

EXPERIMENTAL NEUROLOGY

Connecting Researchers to the Pulse of Neuroscience.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0014-4886Frequency: 12 issues/year

EXPERIMENTAL NEUROLOGY is a premier academic journal published by Academic Press Inc, Elsevier Science, focusing on advancements in the fields of Developmental Neuroscience and Neurology. With an impressive Impact Factor and ranked in the Q1 quartile of both categories—positioning it among the top-tier journals—this publication has established itself as a vital resource for researchers, clinicians, and students alike. Since its inception in 1959, it has fostered the dissemination of cutting-edge research and innovative approaches to understanding neurological function and related disorders. While EXPERIMENTAL NEUROLOGY currently operates under a subscription access model, its rich archives and ongoing contributions to the field continue to inspire and inform the next generation of neurobiologists. The journal also boasts a high ranking in Scopus, placing fourth in Developmental Neuroscience and twentieth in Neurology, indicating its robust influence and scholarly significance. For those committed to advancing knowledge in these critical areas, EXPERIMENTAL NEUROLOGY is an indispensable platform for inquiry and discovery.